Dyadic Applied BioSolutions is a small, early-stage biotech company that develops and commercializes recombinant proteins and enzymes using two proprietary fungal fermentation platforms: C1, originally built for industrial enzyme production and later re-engineered for pharmaceutical use, and Dapibus, purpose-built for non-pharmaceutical markets. Dyadic argues both platforms produce proteins at higher yields and lower cost than conventional systems like CHO cells, E. coli, yeast, and insect cells, with no viral or endotoxin contamination risks. The company targets three markets: life sciences (cell culture media and molecular biology reagents), food and nutrition (animal-free dairy proteins and enzymes), and bio-industrial (enzyme cocktails for biomass conversion and biofuels). Key products include recombinant human albumin commercialized with Proliant under the AlbuFree DX brand, recombinant FGF and DNase I sold in bulk, a bovine chymosin enzyme licensed to Inzymes, and recombinant alpha-lactalbumin in partnership with BRIG BIO. Dyadic's business model is asset-light: the company has only 5 full-time employees, outsources all manufacturing to CDMOs, and relies on partners with existing distribution networks to commercialize products. Revenue comes from direct product sales, profit-sharing arrangements, milestone and license payments, and grants from organizations like the Gates Foundation and CEPI for biopharmaceutical platform validation. Longer-term, Dyadic aims to license C1 to pharmaceutical companies for biologics manufacturing.